Overcoming stromal barriers in pancreatic cancer via size-engineered carrier-free nano-prodrugs
RSC Pharmaceutics · 2026 · 3 (3) · 694-700
DOI: 10.1039/d5pm00364d ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Mengheng Yang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
Carrier-free SNC4DC nanoparticles (30–400 nm) were fabricated by reprecipitation. Smaller particles showed faster SN-38 release and cellular uptake, and 30-nm nanoparticles achieved superior tumor inhibition in pancreatic cancer models.
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Yang, M., Suzuki, R., Koseki, Y., Kodera, S., Saijo, K., Kawakami, H., Tanita, K., Kumar, S., Oka, K., & Kasai, H. (2026). Overcoming stromal barriers in pancreatic cancer via size-engineered carrier-free nano-prodrugs. RSC Pharmaceutics, 3(3), 694-700. https://doi.org/10.1039/d5pm00364d
Vancouver
Yang M, Suzuki R, Koseki Y, Kodera S, Saijo K, Kawakami H, et al. Overcoming stromal barriers in pancreatic cancer via size-engineered carrier-free nano-prodrugs. RSC Pharmaceutics. 2026;3(3):694-700. doi:10.1039/d5pm00364d
BibTeX
@article{Yang2026,
author = {Yang, Mengheng and Suzuki, Ryuju and Koseki, Yoshitaka and Kodera, Shuto and Saijo, Ken and Kawakami, Hisato and Tanita, Keita and Kumar, Sanjay and Oka, Kouki and Kasai, Hitoshi},
title = {Overcoming stromal barriers in pancreatic cancer via size-engineered carrier-free nano-prodrugs},
journal = {RSC Pharmaceutics},
year = {2026},
volume = {3},
number = {3},
pages = {694--700},
doi = {10.1039/d5pm00364d}
}
EUVIMED